DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV.

Citation:
El-Garem, H., M. Abdallah, H. Omar, A. Cordie, S. A. Alem, M. A. Mohey Eldin Elzahry, doaa ghaith, N. H. Abou El-Soud, W. Kamal, A. Elsharkawy, et al., "DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV.", Expert review of gastroenterology & hepatology, pp. 1-6, 2019.

Abstract:

BACKGROUND: The present work aimed at evaluation of the potential dynamic changes in hepatic fibrosis following treatment of chronic HCV using DAAs in patients coinfected with HIV.

PATIENTS AND METHODS: In total, 50 HCV/HIV coinfected patients [age; 34.68 ± 10.38 years, 82% men] were included. For all included patients, liver stiffness measured using transient elastography as well as serum liver fibrosis scores; [fibrosis-4 (FIB-4) score and the aspartate aminotransferase to platelet ratio index (APRI)] were calculated at baseline and at 12 and 24-weeks following 12 weeks therapy of HCV with once daily sofosbuvir 400 mg plus daclatasvir 60 mg.

RESULTS: Most of the included patients (70%, n = 35) were on anti-retroviral therapy. SVR24 was achieved by 93.48% of the patients. There was significant serial improvement in baseline liver stiffness measurement (LSM), FIB-4 and APRI among responders; [LSM: baseline, 7.05 ± 4.84 kPa vs. 5.66 ± 2.63 kPa at SVR24, p < 0.001], [FIB-4: baseline, 1.24 ± 1.08 vs. 0.93 ± 0.64 at SVR24, p 0.001) and (APRI: baseline, 0.725 ± 0.66 vs. 0.36 ± 0.19at SVR24, p 0.001) respectively.

CONCLUSION: Treatment of HCV patients coinfected with HIV using DAAs is associated with a rapid significant regression in hepatic fibrosis, as evaluated by FibroScan, FIB-4, and APRI scores.